Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Bioventus (BVS) stock in plain English

Free brief · no signupStart here
BVSPublished Nov 13, 2026
Bioventus Inc
Healthcare · Medical Devices
Sells ultrasound bone healing devices and hyaluronic acid joint injections directly to healthcare providers.
Assets:
Exogen SystemLow-intensity pulsed ultrasound device for non-invasive fracture repair
Durolane FranchiseSingle-injection hyaluronic acid brand for joint pain management
Durham HeadquartersCentral operational base managing global commercial distribution
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

66
OPS ScoreOperating finances
Latest quote
-6.31%$9.95
$838.40M
12.3×
$586.29M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was BVS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Bioventus (BVS) do?

Bioventus Inc (BVS) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells ultrasound bone healing devices and hyaluronic acid joint injections directly to healthcare providers. Manufactures non-surgical bone stimulation devices and injectable therapies for osteoarthritis joint pain. It is worth $838.40M on the market and sold $586.29M over the last year.

Market cap
$838.40M
P/E ratio
12.3×
Annual sales
$586.29M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 13, 2026

Brands and businesses behind BVS

  • Durolane: A single-injection hyaluronic acid treatment sold to clinicians to relieve joint pain caused by knee osteoarthritis.
  • Exogen: An ultrasound device prescribed to patients to accelerate the healing of broken bones at home.
  • Gelsyn-3: A three-injection hyaluronic acid therapy sold to orthopedic clinics for targeted knee osteoarthritis pain relief.
  • Supartz FX: A multi-injection joint therapy prescribed for temporary relief of osteoarthritis symptoms in patients.

BVS’s flags, in plain English

Each flag is a number from Bioventus’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Insiders Hold

Insiders own 30.8% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Wide Gross Margin

Gross margin of 67.9% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earns Its Keep

Earns 28.2% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.

Thinly Traded

Thinly traded, about 538 shares a day, so prices can swing. Few shares change hands each day, so the price can jump on small orders and buying or selling can cost more.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about BVS

How big is Bioventus?

Bioventus’ market cap is $838.40M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $586.29M: what customers paid the company over the last year, before any costs.

What is BVS’s P/E ratio?

BVS’s P/E ratio is 12.3×. Investors pay about 12.3 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with BVS?

Elevated long-term debt generates substantial interest expenses that limit operating flexibility. That is one risk on Bioventus’ card. Its first risk flag is Thinly Traded, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Bioventus’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. BVS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card